Anti-NSCLC activity in vitro of Hsp90N inhibitor KW-2478 and complex crystal structure determination of Hsp90N-KW-2478-Reference-Cited by-同舟云学术

Anti-NSCLC activity in vitro of Hsp90N inhibitor KW-2478 and complex crystal structure determination of Hsp90N-KW-2478

Published:2021-06 Issue:2 Volume:213 Page:107710
ISSN:1047-8477
Container-title:Journal of Structural Biology
language:en
Short-container-title:Journal of Structural Biology

Author:

Li Hui-Jin,Wang Qi-Sheng^ORCID,Han Wen,Zhou Huan^ORCID,Li Ping,Zhou Fang,Qin Wei,Zhao Dong,Zhou Xin,He Chun-Xia,Xing Lu,Li Peng-Quan,Jin Xi,Yu Feng,He Jian-Hua,Cao Hui-Ling

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Structural Biology

Reference31 articles.

1. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta crystallographica;Adams;Section D, Biological crystallography,2010

2. Therapeutic Uses of HSP90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC);Akram;Curr. Drug Metab.,2018

3. Synthesis and structure-affinity relationship of chlorinated pyrrolidinone-bearing benzenesulfonamides as human carbonic anhydrase inhibitors;Balandis;Bioorg. Chem.,2020

4. Analysis of the HIV-1 Genomic RNA Dimerization Initiation Site Binding to Aminoglycoside Antibiotics Using Isothermal Titration Calorimetry;Bernacchi;Methods in molecular biology (Clifton N.J.),2020

5. Discovery of a novel small inhibitor RJ19 targeting to human Hsp90;Cao;Nuclear Science and Techniques (Nucl Sci Tech),2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hydration-induced damage of tight conglomerates;Chemical Engineering Journal;2024-09

2. HSP90: A promising target for NSCLC treatments;European Journal of Pharmacology;2024-03

3. Heat shock protein 90: biological functions, diseases, and therapeutic targets;MedComm;2024-01-25

4. Comparative Study of the Crystal Structure and Simulated 3D Structure of the Hsp90^N‐Inhibitor Complex;Crystal Research and Technology;2023-06-15

5. The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification;Experimental Hematology & Oncology;2022-05-27